These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25839886)

  • 21. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
    Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
    JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabrafenib-induced neutrophilic panniculitis in a child undergoing dual BRAF-MEK inhibitor therapy for glioblastoma multiforme.
    Young TK; Gutierrez D; Criscito MC; Kim RH; Lakdawala N; Oza VS
    Pediatr Dermatol; 2020 Nov; 37(6):1185-1186. PubMed ID: 32869334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
    Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
    Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research letter: BRAF-inhibitor induced panniculitis - A systematic review.
    Kye Y; Zhao G; Guhan S; Nunes D; Nguyen CV
    J Am Acad Dermatol; 2024 Feb; 90(2):420-423. PubMed ID: 37943239
    [No Abstract]   [Full Text] [Related]  

  • 27. Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
    Bottlaender L; Perier-Muzet M; Lapras V; Thomas L; Dalle S
    Melanoma Res; 2017 Feb; 27(1):68-71. PubMed ID: 27759578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT.
    Broski SM; Moran EK; Glazebrook KN; Nathan MA
    Clin Nucl Med; 2016 Mar; 41(3):e149-51. PubMed ID: 26447389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
    Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
    Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
    Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
    Blackmon JT; Dhawan R; Terry NL; Conry RM
    Melanoma Res; 2017 Apr; 27(2):159-163. PubMed ID: 28252478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
    Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
    Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series.
    Bartlett DJ; Erie AJ; Baffour FI; Broski SM; Glazebrook KN
    Skeletal Radiol; 2021 Jun; 50(6):1257-1262. PubMed ID: 33165713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.
    Falchook GS; Rady P; Hymes S; Nguyen HP; Tyring SK; Prieto VG; Hong DS; Kurzrock R
    JAMA Dermatol; 2013 Mar; 149(3):322-6. PubMed ID: 23552670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
    Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
    Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.